Coeptis Therapeutics Holdings Inc is a pioneering biotechnology firm committed to the advancement of innovative cell and gene therapies targeting oncology and rare diseases. With a promising pipeline supported by proprietary technologies, the company aims to meet significant unmet medical needs, positioning itself for transformative impacts in healthcare. Led by a seasoned management team and bolstered by strategic partnerships, Coeptis is well-positioned to capitalize on growth opportunities within the rapidly evolving biotechnology landscape, highlighting its potential for substantial returns for investors.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-23.93M |
| Operating Margin | 0.00% |
| Return on Equity | -1450.00% |
| Return on Assets | -245.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.06 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $12.70M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |